Search

Displaying results 1181 - 1190 of 7604 in total
  1. Drug

    Omadacycline

    go.drugbank.com/drugs/DB12455
    ApprovedInvestigational

    infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available … classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.

  2. Drug

    Methyltestosterone

    go.drugbank.com/drugs/DB06710
    ApprovedInvestigational

    Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US.

  3. Drug

    Antrafenine

    go.drugbank.com/drugs/DB01419
    Approved

    It is not widely used as it has largely been replaced by newer drugs. … Antrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Non COX-2 selective NSAIDS
  4. Drug

    Netupitant

    go.drugbank.com/drugs/DB09048
    ApprovedInvestigational

    The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo. … Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy

    Synonyms: 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide
  5. Drug

    Lenacapavir

    go.drugbank.com/drugs/DB15673
    ApprovedInvestigational

    [L42995] On December 22, 2022, it was also approved by the FDA.[L44473] … [A244170, A244175, A244180, A244190] Lenacapavir was first globally approved on August 22, 2022 by the European Commission to treat adults with multi-drug resistant HIV infection.

    Synonyms: 1H-CYCLOPROPA(3,4)CYCLOPENTA(1,2-C)PYRAZOLE, N-((1S)-1-(3-(4-CHLORO-3-((METHYLSULFONYL)AMINO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-METHYL-3-(METHYLSULFONYL)-1-BUTYN-1-YL)-2-PYRIDINYL)-2-(3,5-, N-((1S)-1-(3-(4-CHLORO-3-(METHANESULFONAMIDO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-(METHANESULFONYL)-3-METHYLBUT-1-YN-1-YL)PYRIDIN-2-YL)-2-(3,5- DIFLUOROPHENYL)ETHYL)-2-((3BS,4AR)-5,5-DIFLUORO
  6. Drug

    Abciximab

    go.drugbank.com/drugs/DB00054
    ApprovedWithdrawn

    Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules … It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.

  7. Drug

    Tea tree oil

    go.drugbank.com/drugs/DB11218
    ApprovedNutraceutical

    The dermatological use of tea tree oil has been investigated by various studies, where several studies have suggested the uses of this oil for the treatment of acne vulgaris, seborrheic dermatitis, and … It may be referred to as _Melaleuca alternifolia_ oil.

    Mixtures: I Dew Care Tea Tree O Starterkit
  8. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [L45300] On April 24, 2024, sparsentan was granted conditional marketing authorization by the European Commission for the treatment of adults with primary IgAN.[L51559] … [A257330] In February 2023, the use of sparsentan to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression was approved by the FDA under

    Categories: Agents Acting on the Renin-Angiotensin System
  9. Drug

    Hepatitis B Vaccine (Recombinant)

    go.drugbank.com/drugs/DB11627
    ApprovedInvestigationalWithdrawn

    There is no specific treatment for hepatitis. … Infection may also occur by the exposure of mucous surfaces, or intact or damaged skin to other body fluids such as saliva, mucosal secretions and semen.

  10. Drug

    Temozolomide

    go.drugbank.com/drugs/DB00853
    ApprovedInvestigational

    [A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow … It is currently marketed under the trademark TEMODAR® by Merck.[L32033]